| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
|
Purity: ≥98%
Metronidazole (trade names Flagyl, Metro, Trichopol, Vagilen), an imidazole-based and synthetic antibacterial and antiprotozoal drug belonging to the nitroimidazole class, is commonly used for the treatment of protozoa and other baterial infections.For the treatment of a variety of infections, including endocarditis, bacterial vaginosis, and pelvic inflammatory disease, metronidazole can be used either on its own or in combination with other antibiotics. Additionally, it works well for amebiasis, trichomoniasis, giardiasis, and dracunculiasis.
| Targets |
DNA synthesis
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
Metronidazole (135 mg/kg/d; p.o.; 28 d) can penetrate the blood-brain barrier and, when given to rats over an extended period of time, show neurotoxicity[3].
Metronidazole (1 g/L; p.o.; 4 weeks) causes atrophy in skeletal muscle and alters the expression of genes related to metabolic regulation and the peripheral circadian rhythm machinery of the muscle[4]. |
|
| Cell Assay |
Cell Line: Blastocystis sp. Cells
Concentration: 0.1 μg/mL-0.01 mg/mL Incubation Time: 12, 24, 48, 60, 72, 84, 96 hours Result: Decreased cell diameter, as a hallmark of an apoptotic cell, and resulted cell shrinkage. |
|
| Animal Protocol |
Sprague-Dawley (SD) rats (200-220 g)
135 mg/kg Oral gavage; once daily; 28 days |
|
| References |
| Molecular Formula |
C6H9N3O3
|
|
|---|---|---|
| Molecular Weight |
171.15
|
|
| Exact Mass |
171.06
|
|
| Elemental Analysis |
C, 42.10; H, 5.30; N, 24.55; O, 28.04
|
|
| CAS # |
443-48-1
|
|
| Related CAS # |
1460293-84-8 (sodium); 13182-82-6 (acetate); 443-48-1 (free); 13182-89-3 (benzoate); 69198-10-3 (HCl); 443-48-1
|
|
| Appearance |
White to light yellow crystalline powder
|
|
| SMILES |
CC1=NC=C(N1CCO)[N+](=O)[O-]
|
|
| InChi Key |
VAOCPAMSLUNLGC-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3
|
|
| Chemical Name |
2-(2-methyl-5-nitroimidazol-1-yl)ethanol
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (12.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (12.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (12.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 12.5 mg/mL (73.04 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8428 mL | 29.2141 mL | 58.4283 mL | |
| 5 mM | 1.1686 mL | 5.8428 mL | 11.6857 mL | |
| 10 mM | 0.5843 mL | 2.9214 mL | 5.8428 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04478617 | Active Recruiting |
Drug: Metronidazole Vaginal | Post-Op Infection | New York Medical College | July 15, 2020 | Phase 4 |
| NCT01521403 | Active Recruiting |
Drug: Metronidazole Drug: Placebo |
Blastocystis Hominis Infections | University of Lausanne Hospitals | November 2012 | Phase 4 |
| NCT04827537 | Active Recruiting |
Drug: Metronidazole Oral Drug: Placebo Oral |
Giardia Lamblia Infection | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan |
January 1, 2021 | Phase 1 Phase 2 |
| NCT05748145 | Recruiting | Drug: Metronidazole Oral | Colorectal Cancer | Oncology Institute of Southern Switzerland |
September 11, 2023 | Phase 2 |
| NCT04554693 | Recruiting | Drug: Metronidazole Oral Drug: Placebo |
Endometriosis-related Pain Endometriosis |
University of Louisville | October 19, 2020 | Phase 4 |
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
